TRU-SENTIMENT · DeltaNeutral
GKOS Trading Analysis - 11/20/2026 03:36 PM — TRU-SENTIMENT
Options chain · Stock chart · Baseline chart
GKOS (Glaukos Corporation) at $234.96. True Sentiment Bearish, delta 40-60 call 19% / put 81%, call $641,580 vs put $2,755,430. RSI 48.8.
- Symbol
- GKOS
- Price
- $234.96
- Article bias (separate from True Sentiment)
- bullish
- Conviction
- medium
- Published
- 2026-11-20 15:36:00 ET
- Author
- DeltaNeutral staff
TRUE SENTIMENT ANALYSIS (DELTA 40-60 OPTIONS)
True Sentiment Analysis (Delta 40-60 Options)Options flow (Delta 40-60 only) for 2026-11-20 shows:
Call Dollar Volume: $641,580.00 (18.9%) Put Dollar Volume: $2,755,430.00 (81.1%) Total: $3,397,010.00
Sentiment is Bearish. Put contracts 2,116 vs call 336; put trades 4 vs call 7 but put notional dominates. Pure directional positioning suggests near-term defensive or bearish conviction. Divergence: technicals bullish (MACD positive, price > SMA 20/50) but options sentiment bearish — spread recommendation engine returned no trade due to divergence.
Key Statistics: GKOS
Fundamental Snapshot
Valuation
| P/E (trailing) | 97.30 |
| EPS (trailing 12 mo) | $-2.94 |
| Market cap | $13.95B |
| Shares outstanding | 59.2M |
Dividend
| Dividend yield | 0.00% |
Risk & range
| Beta | 0.75 |
| 52-week low | $93.78 |
| 52-week high | $255.19 |
| Historical volatility | 97.4% |
Ownership & trading
| Institutional ownership | 88.0% |
| Average daily volume | 1.9M sh |
Reported figures; no analyst estimates.
📈 Analysis
News Headlines & Context
Glaukos Corporation (GKOS) is a medical technology company focused on surgical and therapeutic solutions for eye diseases such as glaucoma. Recent general-knowledge context for the name includes:
- Glaukos has been expanding its iDose TR sustained-release glaucoma implant commercialization, a recurring catalyst watched by medtech investors.
- The company reported prior-quarter revenue growth backed by international adoption, though profitability remains pressured by commercial scaling.
- No confirmed near-term earnings date is embedded in the provided data, but fiscal year end is listed as 2025-12-01, with historical volatility elevated at 97.41%.
- Pipeline updates or payer coverage decisions for glaucoma devices could act as significant catalysts impacting the stock.
- Context: The embedded options sentiment is bearish even as technical indicators lean bullish, suggesting headline or positioning-driven caution not fully reflected in price trends.
Fundamental Analysis
Based strictly on the provided FUNDAMENTALS data:
| Metric | Value |
|---|---|
| Trailing P/E | 97.30 |
| Trailing EPS | -2.94 |
| Market Cap | $13,954,804,795.00 |
| Shares Outstanding | 59,197,000.00 |
| Dividend Yield | 0.00% |
| Beta | 0.75 |
| 52-Week High | $255.19 |
| 52-Week Low | $93.78 |
| Institutional Ownership | 88.01% |
| Average Volume | 1,912,000.00 |
| Historical Volatility | 97.41% |
Revenue growth (YoY), gross/operating/net margins, ROE, Debt/Equity, and Free Cash Flow are not provided (null). Trailing EPS is negative at -2.94, and trailing P/E is elevated at 97.30, indicating the market prices in future growth despite current net losses. PEG ratio is null, so no growth-adjusted valuation comparison is available. Analyst consensus and target mean price are null. Fundamentals show high institutional ownership (88.01%) and low beta (0.75) but weak current earnings. This diverges from the bullish technical picture (price above SMA 50 and 20), where price strength is not yet supported by positive earnings.
Current Market Position
Current price per indicators is $237.21 (calculated 2026-11-20, based on 2026-11-19 close). Daily history shows 2026-11-19 close at $237.21 after opening $234.80, high $238.55, low $231.61, volume 517,201. Minute bars for 2026-11-19 to 2026-11-20 show opening 2026-11-19 09:30 at $233.79 and final 2026-11-20 15:05 at $234.96, with intraday range roughly $231.61 to $238.55. Intraday momentum is flat-to-slightly-down into close (last bar close $234.96 below prior $235.79).
Technical Analysis
Technical Indicators
Price is above SMA 20 ($227.20) and SMA 50 ($189.80) but below SMA 5 ($241.09), showing short-term cooling within a broader uptrend. RSI 14 at 48.79 is neutral, no overbought/oversold. MACD (15.47) above signal (12.38), histogram positive (3.09) = bullish momentum. Bollinger mid $227.20, price inside upper/lower (no squeeze signal). 30-day range high $255.19, low $159.89; current $237.21 is ~62% up the range.
True Sentiment Analysis (Delta 40-60 Options)
Options flow (Delta 40-60 only) for 2026-11-20 shows:
Call Dollar Volume: $641,580.00 (18.9%) Put Dollar Volume: $2,755,430.00 (81.1%) Total: $3,397,010.00
Sentiment is Bearish. Put contracts 2,116 vs call 336; put trades 4 vs call 7 but put notional dominates. Pure directional positioning suggests near-term defensive or bearish conviction. Divergence: technicals bullish (MACD positive, price > SMA 20/50) but options sentiment bearish — spread recommendation engine returned no trade due to divergence.
Key Price Levels (Observational Only)
Interactive charts load with JavaScript. This text is the crawlable summary.